Navid Sobhani*, Daniele Generali, Giandomenico Roviello, Alberto D'Angelo and Raheleh Roudi
P53 is an unequivocal tumor suppressor altered in most sporadic human cancers. The loss of p53 initiates progression of malignancies and it is characterized by more malignant factors, such as an increase of the risk of cancer cells to become more invasive and potentially metastatic, genomic instability and poor cellular differentiation. Many studies have evaluated the clinical stability of serum p53 antibodies (s-p53-Abs).
PDFShare this article
Journal of Immunobiology received 34 citations as per Google Scholar report
